Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Atebimetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuneering Touts 64% Survival, Fueling Race With Revolution
    Immuneering Touts 64% Survival, Fueling Race With Revolution

    08 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/immuneering-touts-64-1-year-survival-keeping-wheels-turning-race-revolution

    FIERCE BIOTECH
    08 Jan 2026
    Share Share
    Immuneering Announces 12-Month OS Data From Atebimetinib Trial
    Immuneering Announces 12-Month OS Data From Atebimetinib Trial

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209839/0/en/Immuneering-to-Announce-12-Month-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-January-7-2026.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Immuneering Aligns with FDA, EMA on Atebimetinib Phase 3 Trial
    Immuneering Aligns with FDA, EMA on Atebimetinib Phase 3 Trial

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3207312/0/en/Immuneering-Advances-Towards-Dosing-First-Patient-in-Phase-3-Atebimetinib-Trial-for-First-Line-Metastatic-Pancreatic-Cancer-Patients-Securing-Alignment-with-FDA-and-EMA.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Immuneering To Present Q3 2025 Financials & New Clinical Cases
    Immuneering To Present Q3 2025 Financials & New Clinical Cases

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180862/0/en/Immuneering-to-Report-Third-Quarter-2025-Financial-Results-and-Provide-New-Clinical-Case-Studies-on-Wednesday-November-12-2025.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial
    Immuneering To Share OS Data From Ph 2a Pancreatic Cancer Trial

    26 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/26/3157242/0/en/Immuneering-to-Discuss-Recently-Announced-Overall-Survival-Data-from-Phase-2a-Clinical-Trial-of-Atebimetinib-mGnP-in-First-Line-Pancreatic-Cancer-Patients-on-Monday-September-29-20.html

    GLOBENEWSWIRE
    26 Sep 2025
    Share Share
    Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x
    Immuneering Boosts Pancreatic Cancer Survival By Nearly 2x

    25 Sep 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/immuneering-asset-nearly-doubles-overall-survival-in-pancreatic-cancer-after-9-months

    BIOSPACE
    25 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.